A detailed history of Black Rock Inc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 9,559,466 shares of LCTX stock, worth $6.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,559,466
Previous 8,494,395 12.54%
Holding current value
$6.12 Million
Previous $12.6 Million 23.96%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.89 - $1.47 $947,913 - $1.57 Million
1,065,071 Added 12.54%
9,559,466 $9.56 Million
Q1 2024

May 10, 2024

SELL
$0.86 - $1.48 $31,908 - $54,912
-37,103 Reduced 0.43%
8,494,395 $12.6 Million
Q4 2023

Feb 13, 2024

SELL
$0.91 - $1.35 $688,447 - $1.02 Million
-756,536 Reduced 8.15%
8,531,498 $9.3 Million
Q3 2023

Nov 13, 2023

BUY
$1.16 - $1.53 $320,125 - $422,234
275,970 Added 3.06%
9,288,034 $11 Million
Q2 2023

Aug 11, 2023

BUY
$1.26 - $1.53 $6.68 Million - $8.11 Million
5,302,486 Added 142.94%
9,012,064 $12.7 Million
Q1 2023

May 12, 2023

SELL
$1.2 - $1.53 $89,080 - $113,578
-74,234 Reduced 1.96%
3,709,578 $5.56 Million
Q4 2022

Feb 13, 2023

BUY
$1.02 - $1.5 $81,013 - $119,137
79,425 Added 2.14%
3,783,812 $4.43 Million
Q3 2022

Nov 14, 2022

SELL
$1.13 - $1.77 $58,048 - $90,924
-51,370 Reduced 1.37%
3,704,387 $4.19 Million
Q2 2022

Aug 12, 2022

SELL
$1.12 - $1.61 $6.78 Million - $9.75 Million
-6,053,366 Reduced 61.71%
3,755,757 $5.93 Million
Q1 2022

May 12, 2022

SELL
$1.21 - $2.48 $241,258 - $494,479
-199,387 Reduced 1.99%
9,809,123 $15.1 Million
Q4 2021

Feb 10, 2022

BUY
$1.84 - $2.68 $2.68 Million - $3.9 Million
1,456,810 Added 17.04%
10,008,510 $24.5 Million
Q3 2021

Nov 09, 2021

BUY
$2.26 - $2.86 $27,504 - $34,806
12,170 Added 0.14%
8,551,700 $21.6 Million
Q2 2021

Aug 11, 2021

BUY
$2.17 - $3.0 $18.5 Million - $25.6 Million
8,539,530 New
8,539,530 $24.3 Million

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $109M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.